| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Antimicrob. Chemother. (1)
- Clin. Diagn. Lab. Immunol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morikawa K et al. | Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8726002 |
| Sato T et al. | In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. | 2011 | Antimicrob. Agents Chemother. | pmid:21220530 |
| Arain TM et al. | Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. | 1996 | Antimicrob. Agents Chemother. | pmid:8726034 |
| Odenholt-Tornqvist I et al. | Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. | 1995 | Antimicrob. Agents Chemother. | pmid:7695310 |
| Maurin M and Raoult D | In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8109928 |
| Rodvold KA et al. | Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. | 1997 | Antimicrob. Agents Chemother. | pmid:9174209 |
| Giacometti A et al. | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. | 2007 | Antimicrob. Agents Chemother. | pmid:17220421 |
| Ishida K et al. | In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. | 1994 | Antimicrob. Agents Chemother. | pmid:8031048 |
| Bax HI et al. | Tigecycline Potentiates Clarithromycin Activity against Mycobacterium avium In Vitro. | 2016 | Antimicrob. Agents Chemother. | pmid:26883697 |
| Jordan MK et al. | Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. | 2000 | Antimicrob. Agents Chemother. | pmid:10898693 |
| Alder J et al. | Clarithromycin therapy of experimental Treponema pallidum infections in hamsters. | 1993 | Antimicrob. Agents Chemother. | pmid:8494384 |
| Kato M et al. | Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. | 2000 | Antimicrob. Agents Chemother. | pmid:10898707 |
| Xu YF et al. | and Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection. | 2017 | Antimicrob. Agents Chemother. | pmid:28320722 |
| Geng X et al. | The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. | 2017 | Antimicrob. Agents Chemother. | pmid:28242673 |
| Waites KB et al. | In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. | 1988 | Antimicrob. Agents Chemother. | pmid:2973283 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Tomioka H et al. | Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 | Antimicrob. Agents Chemother. | pmid:10582897 |
| Pankuch GA et al. | MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8878583 |
| Chang HR and Pechère JC | In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. | 1988 | Antimicrob. Agents Chemother. | pmid:2837140 |
| Yasuda H et al. | Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8239580 |
| Wakabayashi H et al. | Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. | 2009 | Antimicrob. Agents Chemother. | pmid:19451301 |
| Rastogi N et al. | Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1667250 |
| Lazard T et al. | Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. | 1993 | Antimicrob. Agents Chemother. | pmid:8215285 |
| Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
| Ednie LM et al. | Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8843313 |
| Goldman RC et al. | Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. | 1994 | Antimicrob. Agents Chemother. | pmid:7979278 |
| Roblin PM et al. | Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. | 1994 | Antimicrob. Agents Chemother. | pmid:7979292 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
| Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
| Kamoda O et al. | In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection. | 2006 | Antimicrob. Agents Chemother. | pmid:16940102 |
| Fernandes PB et al. | New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. | 1989 | Antimicrob. Agents Chemother. | pmid:2523688 |
| Dean NC et al. | Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. | 2006 | Antimicrob. Agents Chemother. | pmid:16569825 |
| Cavalieri SJ et al. | Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:7492101 |
| Tateda K et al. | Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891128 |
| Steele-Moore L et al. | In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. | 1999 | Antimicrob. Agents Chemother. | pmid:10383373 |
| Tamaoki J et al. | Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. | 1995 | Antimicrob. Agents Chemother. | pmid:7486901 |
| Kohno Y et al. | Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. | 1989 | Antimicrob. Agents Chemother. | pmid:2526615 |
| Rimbara E et al. | Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. | 2008 | Antimicrob. Agents Chemother. | pmid:18606842 |
| Bolhuis MS et al. | Clarithromycin significantly increases linezolid serum concentrations. | 2010 | Antimicrob. Agents Chemother. | pmid:20837753 |
| Jesus FP et al. | In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25001300 |
| Khan R et al. | T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh. | 2004 | Antimicrob. Agents Chemother. | pmid:15328128 |
| Hoffner SE et al. | Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. | 1993 | Antimicrob. Agents Chemother. | pmid:8392308 |
| Johnson MM et al. | Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. | 1999 | Antimicrob. Agents Chemother. | pmid:10428903 |
| Credito KL et al. | Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. | 1999 | Antimicrob. Agents Chemother. | pmid:10428930 |
| Cynamon MH et al. | Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. | 2000 | Antimicrob. Agents Chemother. | pmid:10991883 |
| Fong IW et al. | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. | 2002 | Antimicrob. Agents Chemother. | pmid:12121899 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Horgen L et al. | Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. | 1998 | Antimicrob. Agents Chemother. | pmid:9797242 |
| Phillips RO et al. | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. | 2014 | Antimicrob. Agents Chemother. | pmid:24323473 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Ménard A et al. | PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:11897613 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Hotomi M et al. | Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. | 2007 | Antimicrob. Agents Chemother. | pmid:17698631 |
| Berg HF et al. | Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. | 2004 | Antimicrob. Agents Chemother. | pmid:15504839 |
| Brown BA et al. | Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. | 1992 | Antimicrob. Agents Chemother. | pmid:1317144 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Friedman ND et al. | Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. | 2016 | Antimicrob. Agents Chemother. | pmid:26883709 |
| Bastian S et al. | Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. | 2011 | Antimicrob. Agents Chemother. | pmid:21135185 |
| De R et al. | Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. | 2009 | Antimicrob. Agents Chemother. | pmid:19204190 |
| Wolinsky E | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8031406 |
| Ramón-GarcÃa S et al. | Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 | Antimicrob. Agents Chemother. | pmid:21576426 |
| Mathis A et al. | Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis. | 2005 | Antimicrob. Agents Chemother. | pmid:16048933 |
| Cohen Y et al. | Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. | 1992 | Antimicrob. Agents Chemother. | pmid:1332586 |
| Dai G et al. | Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:16048962 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Shinkai M et al. | Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. | 2006 | Antimicrob. Agents Chemother. | pmid:16641444 |
| English ML et al. | Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. | 2012 | Antimicrob. Agents Chemother. | pmid:22290969 |
| Anton E et al. | Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. | 2015 | Antimicrob. Agents Chemother. | pmid:26711765 |
| Klemens SP and Cynamon MH | Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. | 1994 | Antimicrob. Agents Chemother. | pmid:7979271 |
| Ji B et al. | Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. | 2008 | Antimicrob. Agents Chemother. | pmid:18391038 |
| Atkinson BA et al. | Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. | 1995 | Antimicrob. Agents Chemother. | pmid:8619588 |
| Choi GE et al. | Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. | 2012 | Antimicrob. Agents Chemother. | pmid:22564831 |
| Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
| Wang G et al. | Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. | 2001 | Antimicrob. Agents Chemother. | pmid:11181351 |
| Ishikawa C et al. | Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes. | 2009 | Antimicrob. Agents Chemother. | pmid:19258275 |
| Alhajlan M et al. | Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. | 2013 | Antimicrob. Agents Chemother. | pmid:23545534 |
| Burucoa C et al. | T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:15673794 |
| Woosley LN et al. | CEM-101 activity against Gram-positive organisms. | 2010 | Antimicrob. Agents Chemother. | pmid:20176910 |
| Bermudez LE et al. | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. | 2007 | Antimicrob. Agents Chemother. | pmid:17296742 |
| Finch R et al. | Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. | 2002 | Antimicrob. Agents Chemother. | pmid:12019085 |
| Prazeres Magalhães P et al. | Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. | 2002 | Antimicrob. Agents Chemother. | pmid:12019131 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Lee JH et al. | Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. | 2005 | Antimicrob. Agents Chemother. | pmid:15793150 |
| Ji B et al. | Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834886 |
| Nash KA | Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. | 2001 | Antimicrob. Agents Chemother. | pmid:11353601 |
| Fernandes PB et al. | Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. | 1987 | Antimicrob. Agents Chemother. | pmid:2957954 |
| Mor N and Esfandiari A | Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. | 1997 | Antimicrob. Agents Chemother. | pmid:9303411 |
| Alder JD et al. | Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. | 1998 | Antimicrob. Agents Chemother. | pmid:9736568 |
| Polis MA et al. | Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. | 1997 | Antimicrob. Agents Chemother. | pmid:9257746 |
| Walker KJ et al. | Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. | 1994 | Antimicrob. Agents Chemother. | pmid:7811010 |
| Bernut A et al. | In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. | 2014 | Antimicrob. Agents Chemother. | pmid:24798271 |
| Spyridaki I et al. | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. | 2009 | Antimicrob. Agents Chemother. | pmid:19332671 |
| Jones RN et al. | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. | 2010 | Antimicrob. Agents Chemother. | pmid:20660671 |
| Wenisch C et al. | Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. | 1996 | Antimicrob. Agents Chemother. | pmid:8878577 |
| Koh WJ et al. | Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. | 2013 | Antimicrob. Agents Chemother. | pmid:23183432 |
| Kosowska-Shick K et al. | Comparative antipneumococcal activities of sulopenem and other drugs. | 2009 | Antimicrob. Agents Chemother. | pmid:19307366 |
| Berti AD et al. | Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. | 2012 | Antimicrob. Agents Chemother. | pmid:22802248 |
| Zhanel GG and Karlowsky JA | In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. | 2009 | Antimicrob. Agents Chemother. | pmid:19139284 |
| Donati M et al. | In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. | 2010 | Antimicrob. Agents Chemother. | pmid:20855744 |